Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling

Abstract

Objective:

To identify cost estimates related to myocardial infarction (MI) or stroke in patients with type 2 diabetes mellitus (T2DM) for use in economic models.

Methods:

A systematic literature review was conducted. Electronic databases and conference abstracts were screened against inclusion criteria, which included studies performed in patients who had T2DM before experiencing an MI or stroke. Primary cost studies and economic models were included. Costs were converted to 2012 pounds sterling.

Results:

Fifty-four studies were identified: 13 primary cost studies and 41 economic evaluations using secondary sources for complication costs. Primary studies provided costs from 10 countries. Estimates for a fatal event ranged from £2482–£5222 for MI and from £4900–£6694 for stroke. Costs for the year a non-fatal event occurred ranged from £5071–£29,249 for MI and from £5171–£38,732 for stroke. Annual follow-up costs ranged from £945–£1616 for an MI and from £4704–£12,926 for a stroke. Economic evaluations from 12 countries were identified, and costs of complications showed similar variability to the primary studies.

Discussion:

The costs identified within primary studies varied between and within countries. Many studies used costs estimated in studies not specific to patients with T2DM. Data gaps included a detailed breakdown of resource use, which affected the ability to compare data across countries.

Conclusions:

In the development of economic models for patients with T2DM, the use of accurate estimates of costs associated with MI and stroke is important. When country-specific costs are not available, clear justification for the choice of estimates should be provided.

Keywords::

• Economic evaluation
• Stroke
• Myocardial infarction
• Type 2 diabetes mellitus
• Cost

Transparency

Declaration of funding

This study was funded by Boehringer Ingelheim GmbH. V. Brennan and C. Copley-Merriman drafted this manuscript, and all authors subsequently reviewed and modified the draft to develop this submitted manuscript.

Declaration of financial/other relationships

R. Palencia and B. Hass are employees of Boehringer Ingelheim GmbH. V. Brennan, A. Colosia, C. Copley-Merriman, and J. Mauskopf are employees of RTI Health Solutions. This study was conducted by RTI Health Solutions under the direction of Boehringer Ingelheim GmbH and was funded by Boehringer Ingelheim GmbH. JME Peer Reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgements

The authors thank Maria Fernandez, Cheryl Coon, Jake Libiecki, and Doreen McBride for translation of non-English articles, and Matthew Cawson for assistance with standardizing costs.